Table of Contents Author Guidelines Submit a Manuscript

This article has been retracted as Figures 3(a) and 3(b) in this article are identical to Figures 2(a) and 2(b) in the published article by Chang-qiang Tan, Xia Gao, Wen-jun Cai, Xiao-yun Qian, Ling Lu, and He Huang, “Experimental Study of Local Inner Ear Gene Therapy for Controlling Autoimmune Sensorineural Hearing Loss,” BioMed Research International, vol. 2014, Article ID 134658, 10 pages, 2014. doi: 10.1155/2014/134658, but they represent different experiments.

View the original article here.


  1. C.-Q. Tan, X. Gao, L. Guo, and H. Huang, “Exogenous IL-4-expressing bone marrow mesenchymal stem cells for the treatment of autoimmune sensorineural hearing loss in a guinea pig model,” BioMed Research International, vol. 2014, Article ID 856019, 10 pages, 2014.
BioMed Research International
Volume 2014 (2014), Article ID 856019, 10 pages
Research Article

Exogenous IL-4-Expressing Bone Marrow Mesenchymal Stem Cells for the Treatment of Autoimmune Sensorineural Hearing Loss in a Guinea Pig Model

1State Key Laboratory of Materials-Oriented Chemical Engineering, College of Biotechnology and Pharmaceutical Engineering, Nanjing University of Technology, No. 5 Xinmofan Road, Nanjing, Jiangsu 210009, China
2Department of Otolaryngology-Head and Neck Surgery, Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu 210008, China
3Department of Otolaryngology, Nanjing Stomatological Hospital, Nanjing, Jiangsu 210008, China

Received 15 January 2014; Revised 4 March 2014; Accepted 26 March 2014; Published 22 April 2014

Academic Editor: Elena Jones

Copyright © 2014 Chang-qiang Tan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Bone marrow mesenchymal stem cells (BMSCs) expressing recombinant IL-4 have the potential to remediate inflammatory diseases. We thus investigated whether BMSCs expressing exogenous IL-4 could alleviate autoimmune sensorineural hearing loss. BMSCs isolated from guinea pigs were transfected with recombinant lentivirus expressing IL-4. A total of 33 animals were divided into three groups. Group A received scala tympani injection of IL-4-expressing BMSCs, and Group B received control vector-expressing BMSCs, and Group C received phosphate-buffered saline. The distribution of implanted BMSCs in the inner ears was assessed by immunohistochemistry and fluorescence microscopy. Auditory brain-stem response (ABR) was monitored to evaluate the auditory changes. Following BMSCs transplantation, the threshold levels of ABR wave III decreased in Groups A and B and significant differences were observed between these two groups . Transplanted BMSCs distributed in the scala tympani and scala vestibuli. In some ears with hearing loss, there was a decrease in the number of spiral ganglion cells and varying degrees of endolymphatic hydrops or floccule. Following transplantation, the lentivirus-infected BMSCs migrated to the inner ear and produced IL-4. Our results demonstrate that, upon transplantation, BMSCs and BMSCs expressing recombinant IL-4 have the ability to remediate the inflammatory injury in autoimmune inner ear diseases.